![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -3.28% | 14.75 | 14.50 | 15.00 | 15.25 | 14.50 | 15.25 | 68,434 | 14:37:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.19 | 13.91M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/5/2017 10:41 | remember months ago there was talk of naked short trading of opti from the stock exchange borse berlin. could this be anything to do with the drop | ![]() manc10 | |
05/5/2017 10:37 | There's not much patience on aim. Investors want all the jam today, not prepared to wait! This is a medium to long term stock in my view. | bdog51 | |
05/5/2017 09:52 | Hopefully next week's announcements will include some actual material sales linked to them. If not, then the news is already in the public domain and the share price will have little positive reaction. | ![]() diablo26261 | |
05/5/2017 09:50 | Good post risky. can i ask where you get the 200k figure from dsm from? and why do you expect figures from lp ldl launch? | slartybartfaster | |
05/5/2017 09:48 | please tell smithy, did you short bnn from 140p to 60p and go long ahead of a ramped recovery to 80p? You cant see red flags even when they are pointed out to you. Now you post nonsense about an innovative start up company with a fixed cost base moving from an rd phases to commercial phases across multiple platforms. Please do go short, you will have to close before i do. | slartybartfaster | |
05/5/2017 09:39 | MM you are right about sbtx ipo and share distribution being a pr disaster. Wouldnt you expect the bod to learn from this? i do. I dont agree opti has fallen on the back of 4d as you imply. it has more to do with your original point. You are wrong about revenues, they are growing and are expected to accelerate as tata comes on stream, lp ldl builds and all the time the cost base remains around 80/100k per month. I found your comments about bod trust an odd one considering what trak bod did. They over stated revenues and adjusted them 2 or was it 3 times. Now that is quite a difference than a pr disaster, yet you seem to have grown in confidence where trak are concerned. Sorry mm but you appear to make certain facts suit your investment agenda and it is not at all consistent. | ![]() pglancy | |
05/5/2017 09:28 | monkey, dont suppose you have ever spoken about a holding of yours in favourable terms. No of course not, you prefer run around posting childish on liners. Risky posted realist events most here expect. Tell us have you ever offered a detailed opinion on any investment you thought was worth a punt? I bet you plead the 5th like michaelmouse. | ![]() incanus | |
05/5/2017 09:21 | No Ramping Monkey, just facts, Risky could have also said that our partners at Manchester university are looking for other ways of treating terrible illnesses,so we could have even more products on the shelves in years to come ( jam tomorrow ) but let's not get a head of our selves, next week will be very interesting. DIAMOND. | ![]() diamond fibre | |
05/5/2017 09:12 | Risky....four trades yesterday in a short period of time all within about two minutes and all of low amounts that triggered a fall gave me my answer. And I do believe that soh should not be involved with a web site that openly promotes short trading. Also if there is this sort of activity then your work is made easier if you know about the seller and their intentions. This looks to close to the release of good news not to smell a bit fishy... | ![]() bobdown2 | |
05/5/2017 08:55 | With all this sudden negativity it's more than likely to be shorts which has worked out a treat. Not really ramping just saying it how it is. Clearly still risk from our partners and others but the future of this company currently looks very good. | ![]() riskybusiness1 | |
05/5/2017 08:44 | All this ramping and the share price has tanked. | ![]() monkeywench1 | |
05/5/2017 08:44 | So why are they selling if the potential here is so compelling?? | talkingtrade | |
05/5/2017 08:42 | Nope just someone either selling multiple 10,000 chunks or even short selling and spooking the market. They have done a great job to be fair. All the way from 85p. Some mornings dropping 100k +. Half the daily volume. Created s great opportunity however. | ![]() riskybusiness1 | |
05/5/2017 08:29 | Risky..Great post among others. Wonder why market hasn't woken up to this.Could it be "they don't understand the science" | talkingtrade | |
05/5/2017 08:26 | Slimbiome - tata one of worlds largest companies developing their own products to launch themselves late 2017. Cost to opti £0....go figure selling well from soft launch - validating science attracting tata. Slim fast contract signed last year.Lpldl - manufacture agreement with Sacco one of worlds largest probiotics manufacturers. Cost £0 even get %50 of profit of everything sold. Distributors hlh biopharma 100,000 units sold pre launch. Unnamed partner for vitafoods launch + many to be announced following launch. Costs to opti virtually £0. Lpldl as s brand becomes known in the market. Sales and reputation buildOptibiotics deal with dsm suspected £200k from them in results. Worlds largest ingredients supplier. Commercial news with figures could be announced anytime. They sell the product opti gets revenues. Cost £0.Sweetbiotix - early launch 2017 early 18. Product development and demand better than anticipated. Partners to be announced. Opti cost 0£.Just some of a long line of coming revenues. These partners pay for the marketing and sales and pay opti because of the inability to copy the science and patents. Costs remain flat £80k per month cash burn whilst revenues build from multiple partners. Opti has no manufacturer or distribution costs. It just s gets paid once the science has been made in to products. To say this company will never make a profit is ridiculous. Any one of the many great products could make this company profitable. Great products, massive markets, low low costs. Everything looks ok to me | ![]() riskybusiness1 | |
05/5/2017 08:23 | Well whoever it who's selling has done an impressively grand job! :( | ![]() judijudi | |
05/5/2017 08:14 | Not seeing buyers at these levels...If this drops further can't wait for the "in line with market sentiment" quote... | talkingtrade | |
05/5/2017 08:05 | Whatever is said now, the "spin-off" of SBTX has been a PR disaster. Make no mistake, investors were expecting "free shares" in the IPO since this was strongly hinted at. Trust has been lost, particularly in regard to what might happen with future spin offs. As I said when this idea of spin offs was announced, they are just fund raisings in disguise. The trouble is, the lack of clarity and trust with the SBTX debacle would be bad enough if the company was profitable, cash generative and had a proven business model. Opti and sbtx are non of those, and as such they are both widely overpriced at their current heady valuations. They are loss making, cash burning companies whose route to profitability (if at all) is years away. In short, that is why I believe that the share price price of both is mirroring that of dddd, where it eventually went into freefall. Reality catching up with expectations. Aimho of course. Good luck. | ![]() michaelmouse | |
05/5/2017 08:05 | Selling below bid,another red day on the line :( | ![]() scotty1 | |
05/5/2017 08:02 | slartybartfaster - 04 May 2017 - 21:09 - 23118 of 23121 - 5pair trade. Long BNN, short OPTI would be my trade. imo | ![]() tsmith2 | |
05/5/2017 07:09 | In the last 12 months commercial deals have focused on joint development, cost sharing, or option agreements with partners contributing funding in return for certain future rights. The next 12 months will see the Company transition from a technology company to a product company building revenues streams from a diverse range of products. This process started in August 2016 with the launch of GoFigure(R) products and continues with the launch of our LP(LDL) (R) cholesterol reducing strain in May 2017. We hope the launch of first generation SweetBiotix(R) later this year will complete the launch of innovative microbiome products across all our technology platforms. | ![]() parob | |
05/5/2017 06:52 | Lol the rampers need to understand opportunity cost. | ![]() monkeywench1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions